At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (KEYFORM-007)
In Brief
A Phase 3 clinical trial evaluating favezelimab/pembrolizumab, regorafenib, and 1 other intervention for Colorectal Cancer. Completed, enrolled 441 participants across 152 sites in 21 countries.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regorafenib and TAS-102 (trifluridine and tipiracil). The primary study hypothesis is that coformulated favezelimab/pembrolizumab (MK-4280A) is superior to standard of care with respect to overall survival.
Study Details
Timeline
Interventions
Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion
Oral
Oral